Latanoprost

Drug Profile

Latanoprost

Alternative Names: Latanoprost ophthalmic solution - Pfizer; PhXA41; Xalatan

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 27 Mar 2015 Latanoprost is approved in the European Union for Glaucoma and Ocular hypertension
  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
  • 25 Jan 2012 Generic equivalent available in Italy, Spain, Iceland, Switzerland, Hungary, Bulgaria & Czech Republic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top